|

STAR0602 Clinical Trials

2 actively recruiting trials across 2 locations

No change since August 2026

Also known as: Invikafusp alfa

Pipeline

Phase 1/2: 2

Top Sponsors

  • Marengo Therapeutics, Inc.2

Indications

  • Cancer2
  • Vulvar Diseases1
  • Vulvar Neoplasms1
  • Triple Negative Locally Advanced Non-resectable Breast Cancer1
  • HR+, HER2-, Advanced Breast Cancer1

Los Angeles, California1 trial

A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors

USC Norris Comprehensive Cancer Center

Phase 1/2

Sacramento, California1 trial

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

UC Davis Comprehensive Cancer Center

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.